BCL2 and neoplasm: The combined management of RES with temozolomide caused cell cycle arrest, decreases of MMP9, and anti‐apoptosis protein Bcl‐2 in the human GB cell line (SHG44), and reduced the volume of the tumor in an orthotopic xenograft model of GB [71].